Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Canada
/
Pharmaceuticals & Biotech
/
Trulieve Cannabis
TRUL
Trulieve Cannabis
Regulatory Hurdles Will Limit Florida Expansion But Spark Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
08 Aug 25
Updated
08 Aug 25
1
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CA$11.00
1.3% overvalued
intrinsic discount
08 Aug
CA$11.15
Loading
1Y
-18.7%
7D
47.9%
Author's Valuation
CA$11.0
1.3% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CA$11.0
1.3% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-508m
1b
2016
2018
2020
2022
2024
2025
2026
2028
Revenue US$1.2b
Earnings US$61.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
2.39%
Pharma revenue growth rate
1.09%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.30%
Calculation
US$61.48m
Earnings '28
x
31.57x
PE Ratio '28
=
US$1.94b
Market Cap '28
US$1.94b
Market Cap '28
/
202.93m
No. shares '28
=
US$9.56
Share Price '28
US$9.56
Share Price '28
Discounted to 2025 @ 6.30% p.a.
=
US$7.96
Fair Value '25
US$7.96
Fair Value '25
Converted to CAD @ 1.3753 USD/CAD Exchange Rate
=
CA$10.95
Fair Value '25
